Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
8.73 USD | +0.23% |
|
+7.12% | -8.11% |
Jul. 09 | National Bank Cuts DRI Healthcare Target to $17.50, Maintains Outperform | MT |
Jul. 09 | DRI Healthcare Price Target Lowered to $18.50 at CIBC | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company is in a robust financial situation considering its net cash and margin position.
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
- The company is one of the best yield companies with high dividend expectations.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 100.1 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 5.13 times its current sales, is high.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.11% | 478M | - | ||
+63.03% | 856B | C+ | ||
+38.95% | 631B | B | ||
-3.89% | 359B | C+ | ||
+16.02% | 325B | B- | ||
+8.92% | 297B | C+ | ||
+5.89% | 234B | A+ | ||
+16.53% | 226B | B- | ||
+15.58% | 177B | C+ | ||
+1.93% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- DHT.U Stock
- DHT.U Stock
- Ratings DRI Healthcare Trust